Targeting the EGFR and the PKB pathway in cancer.

Abstract excerpt

The EGFR and PKB pathways are frequently activated in cancer, so are prime targets for cancer therapy. To this end, new inhibitors are being tested. EGFR inhibitors as single therapy have little benefit, although therapies that evoke an antitumor immune response are more effective. Resistance mutations within the EGFR are common, as is activation of the antiapoptotic PKB pathway via alternative tyrosine kinase...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Isoenzymes
• Share to Neoplastic Stem Cells
• Share to Phosphatidylinositol 3-Kinases